Oncimmune Holdings plc has placed and converted debt into equity
Oncimmune Holdings plc has raised US$2.9 million (£2.3 million) by placing and converting debt into equity to advance its pioneering work in autoantibody profiling and biomarker discovery, along with an additional US$4.1 million (€4 million) from debt conversion.
Oncimmune Holdings plc develops and commercializes technologies for cancer diagnosis in the UK, North America, Europe and beyond. The company offers EarlyCDT-Lung, a blood test for the early detection of lung cancer. Additionally, Oncimmune develops SeroTag, a platform for discovering and validating biomarkers to help stratify patients across multiple cancer indications, infectious diseases and autoimmune conditions. The company also offers NavigAID disease-specific stratification panels. Founded in 2015, Oncimmune is based in Nottingham, UK.
Oaklins Cavendish, one of Oaklins’ member firms in the UK, advised Oncimmune Holdings plc on this transaction.
Sprechen Sie mit dem Deal Team
Transaktionen
Die Lindenhofgruppe veräussert ihre Mehrheitsbeteiligung an der LabPoint an Affidea Switzerland
Die LabPoint Medizinische Laboratorien AG wurde von Affidea Switzerland AG übernommen. Mit Affidea hat die Lindenhofgruppe AG einen starken strategischen Partner für die Weiterentwicklung der LabPoint gewonnen. Die Lindenhofgruppe bleibt bedeutende Aktionärin und Grosskundin des Unternehmens. Damit schafft sie die Grundlage für eine nachhaltige Weiterentwicklung von LabPoint unter einer neuen Ankeraktionärin. LabPoint soll ihre Position in der Labordiagnostik weiter stärken und gezielt ausbauen.
Mehr erfahrenOmer Engineering has completed an IPO
Omer Engineering Ltd. has successfully launched its IPO on the Tel Aviv Stock Exchange, pricing shares as part of a plan to raise approximately US$94 million at an implied pre-money valuation of around US$313 million. The offering included both newly issued shares and a secondary sale by existing shareholders, who retained a significant majority stake post-IPO. This transaction underscores strong investor interest in scaling the company’s operations and enhancing its capital.
Mehr erfahrenSmart Capital has finalized a rights issue
Smart Capital S.p.A. has finalized a rights issue to continue executing its growth plan and increase its investment capacity. The fundraising supports the expansion of its investment portfolio and the strengthening of its positions in higher-quality investee companies with stronger growth prospects.
Mehr erfahren